Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment
Yakir Rottenberg, Albert Grinshpun, Iddo Z. Ben‐Dov, Esther Djian, Dana G. Wolf, Luna Kadouri
Abstract
This cohort study evaluates the short-term humoral response to a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing acute systemic therapy for solid tumors.
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakMEDLINEVirologyInternal medicineDiseaseInfectious disease (medical specialty)LawPolitical scienceOutbreakSARS-CoV-2 and COVID-19 ResearchCancer Immunotherapy and BiomarkersCOVID-19 Clinical Research Studies